Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR

被引:61
|
作者
Rahman, Mahboob [1 ]
Ford, Charles E. [1 ]
Cutler, Jeffrey A. [1 ]
Davis, Barry R. [1 ]
Piller, Linda B. [1 ]
Whelton, Paul K. [1 ]
Wright, Jackson T., Jr. [1 ]
Barzilay, Joshua I. [1 ]
Brown, Clinton D. [1 ]
Colon, Pedro J., Sr. [1 ]
Fine, Lawrence J. [1 ]
Grimm, Richard H., Jr. [1 ]
Gupta, Alok K. [1 ]
Baimbridge, Charles [1 ]
Haywood, L. Julian [1 ]
Henriquez, Mario A. [1 ]
Ilamaythi, Ekambaram [1 ]
Oparil, Suzanne [1 ]
Preston, Richard [1 ]
机构
[1] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA
关键词
CHRONIC KIDNEY-DISEASE; BLOOD-PRESSURE CONTROL; HYPERTENSIVE PATIENTS; PROGRESSION; ASSOCIATION; AMERICAN; DESIGN;
D O I
10.2215/CJN.07800811
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives CKD is common among older patients. This article assesses long-term renal and cardiovascular outcomes in older high-risk hypertensive patients, stratified by baseline estimated GFR (eGFR), and long-term outcome efficacy of 5-year first-step treatment with amlodipine or lisinopril, each compared with chlorthalidone. Design, setting, participants, & measurements This was a long-term post-trial follow-up of hypertensive participants (n=31,350), aged >= 55 years, randomized to receive chlorthalidone, amlodipine, or lisinopril for 4-8 years at 593 centers. Participants were stratified by baseline eGFR (ml/min per 1.73 m(2)) as follows: normal/increased (>= 90; n=8027), mild reduction (60-89; n=17,778), and moderate/severe reduction (<60; n=5545). Outcomes were cardiovascular mortality (primary outcome), total mortality, coronary heart disease, cardiovascular disease, stroke, heart failure, and ESRD. Results After an average 8.8-year follow-up, total mortality was significantly higher in participants with moderate/severe eGFR reduction compared with those with normal and mildly reduced eGFR (P<0.001). in participants with an eGFR <60, there was no significant difference in cardiovascular mortality between chlorthalidone and amlodipine (P=0.64), or chlorthalidone and lisinopril (P=0.56). Likewise, no significant differences were observed for total mortality, coronary heart disease, cardiovascular disease, stroke, or ESRD. Conclusions CKD is associated with significantly higher long-term risk of cardiovascular events and mortality in older hypertensive patients. By eGFR stratum, 5-year treatment with amlodipine or lisinopril was not superior to chlorthalidone in preventing cardiovascular events, mortality, or ESRD during 9-year follow-up. Because data on proteinuria were not available, these findings may not be extrapolated to proteinuric CKD. Clin J Am Soc Nephrol 7: 989-1002, 2012. doi: 10.2215/CJN.07800811
引用
收藏
页码:989 / 1002
页数:14
相关论文
共 50 条
  • [31] The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?
    Beevers, DG
    Lee, KW
    Lip, GYH
    JOURNAL OF HUMAN HYPERTENSION, 2003, 17 (06) : 367 - 372
  • [32] The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?
    D G Beevers
    K W Lee
    G Y H Lip
    Journal of Human Hypertension, 2003, 17 : 367 - 372
  • [33] Stroke results in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Oparil, S
    Davis, BR
    Nwachuku, C
    Pressel, S
    deLeon, B
    STROKE, 2004, 35 (01) : 235 - 235
  • [34] Impact of the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) on physician prescribing patterns and patient utilization of antihypertensive medications
    Liu, X
    Yu, W
    Yokoyama, K
    VALUE IN HEALTH, 2004, 7 (03) : 334 - 334
  • [35] Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone - The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Furberg, CD
    Wright, JT
    Davis, BR
    Cutler, JA
    Alderman, M
    Black, H
    Cushman, W
    Grimm, R
    Haywood, LJ
    Leenen, F
    Oparil, S
    Perry, HM
    Probstfield, J
    Whelton, P
    Payne, G
    Nwachuku, C
    Gordon, D
    Proschan, M
    Frommer, P
    Einhorn, P
    Hawkins, M
    Ford, C
    Pressel, S
    Piller, L
    Lusk, C
    Bettencourt, J
    Kimmel, B
    Geraci, T
    Walsh, S
    Rahman, M
    Juratovac, A
    Pospisil, R
    Brennan, K
    Carroll, L
    Sullivan, S
    Barone, G
    Christian, R
    Feldman, S
    Lucente, T
    Lewis, CE
    Jenkins, K
    McDowell, P
    Johnson, J
    Kingry, C
    Letterer, R
    Margolis, K
    Holland, L
    Jaeger-Fox, B
    Williamson, J
    Louis, G
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (15): : 1967 - 1975
  • [36] Heart failure results in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Davis, B
    EUROPEAN HEART JOURNAL, 2004, 25 : 122 - 122
  • [37] Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone
    Linda B Piller
    Barry R Davis
    Jeffrey A Cutler
    William C Cushman
    Jackson T Wright
    Jeff D Williamson
    Frans HH Leenen
    Paula T Einhorn
    Otelio S Randall
    John S Golden
    L Julian Haywood
    Current Controlled Trials in Cardiovascular Medicine, 2002, 3
  • [38] Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants assigned to doxazosin and chlorthalidone
    Piller, LB
    Davis, BR
    Cutler, JA
    Cushman, WC
    Wright, JT
    Williamson, JD
    Leenen, FH
    Einhorn, PT
    Randall, OS
    Golden, JS
    Haywood, LJ
    CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2002, 3 (1):
  • [39] Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia - Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Whelton, PK
    Barzilay, J
    Cushman, WC
    Davis, BR
    Iiamathi, E
    Kostis, JB
    Leenen, FHH
    Louis, GT
    Margolis, KL
    Mathis, DE
    Moloo, J
    Nwachuku, C
    Panebianco, D
    Parish, DC
    Pressel, S
    Simmons, DL
    Thadani, U
    ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (12) : 1401 - 1409
  • [40] Heart failure with preserved and impaired left ventricular systolic function in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Davis, Barry R.
    Simpson, Lara M.
    Black, Henry R.
    Cushman, Wililam C.
    Einhorn, Paula T.
    Farber, Michael A.
    Ford, Charles E.
    Levy, Daniel
    Massie, Barry M.
    Nawaz, Shah
    Nawaz, Shah
    CIRCULATION, 2006, 114 (18) : 571 - 571